Neural substrates of propranolol-induced impairments in the reconsolidation of nicotine-associated memories in smokers.


Journal

Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664

Informations de publication

Date de publication:
24 08 2021
Historique:
received: 30 09 2020
accepted: 03 08 2021
revised: 07 03 2021
entrez: 25 8 2021
pubmed: 26 8 2021
medline: 12 10 2021
Statut: epublish

Résumé

The majority of smokers relapse even after successfully quitting because of the craving to smoking after unexpectedly re-exposed to smoking-related cues. This conditioned craving is mediated by reward memories that are frequently experienced and stubbornly resistant to treatment. Reconsolidation theory posits that well-consolidated memories are destabilized after retrieval, and this process renders memories labile and vulnerable to amnestic intervention. This study tests the retrieval reconsolidation procedure to decrease nicotine craving among people who smoke. In this study, 52 male smokers received a single dose of propranolol (n = 27) or placebo (n = 25) before the reactivation of nicotine-associated memories to impair the reconsolidation process. Craving for smoking and neural activity in response to smoking-related cues served as primary outcomes. Functional magnetic resonance imaging was performed during the memory reconsolidation process. The disruption of reconsolidation by propranolol decreased craving for smoking. Reactivity of the postcentral gyrus in response to smoking-related cues also decreased in the propranolol group after the reconsolidation manipulation. Functional connectivity between the hippocampus and striatum was higher during memory reconsolidation in the propranolol group. Furthermore, the increase in coupling between the hippocampus and striatum positively correlated with the decrease in craving after the reconsolidation manipulation in the propranolol group. Propranolol administration before memory reactivation disrupted the reconsolidation of smoking-related memories in smokers by mediating brain regions that are involved in memory and reward processing. These findings demonstrate the noradrenergic regulation of memory reconsolidation in humans and suggest that adjunct propranolol administration can facilitate the treatment of nicotine dependence. The present study was pre-registered at ClinicalTrials.gov (registration no. ChiCTR1900024412).

Identifiants

pubmed: 34429396
doi: 10.1038/s41398-021-01566-6
pii: 10.1038/s41398-021-01566-6
pmc: PMC8385067
doi:

Substances chimiques

Nicotine 6M3C89ZY6R
Propranolol 9Y8NXQ24VQ

Banques de données

ChiCTR
['ChiCTR1900024412']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

441

Informations de copyright

© 2021. The Author(s).

Références

WHO. Systematic review of the link between tobacco and poverty. Geneva, Switzerland: World Health Organization; 2011.
WHO. WHO report on the global tobacco epidemic, 2015: raising taxes on tobacco. 2015;48:261–70.
Torregrossa MM, Corlett PR, Taylor JR. Aberrant learning and memory in addiction. Neurobiol Learn Mem. 2011;96:609–23.
pubmed: 21376820 pmcid: 3138832 doi: 10.1016/j.nlm.2011.02.014
Berridge KC, Robinson TE. Liking, wanting, and the incentive-sensitization theory of addiction. Am Psychol. 2016;71:670–9.
pubmed: 27977239 pmcid: 5171207 doi: 10.1037/amp0000059
Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993;18:247–91.
pubmed: 8401595 doi: 10.1016/0165-0173(93)90013-P
Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH. Attentional bias predicts outcome in smoking cessation. Health Psychol. 2003;22:378–87.
pubmed: 12940394 pmcid: 2244587 doi: 10.1037/0278-6133.22.4.378
Carpenter MJ, Saladin ME, DeSantis S, Gray KM, LaRowe SD, Upadhyaya HP. Laboratory-based, cue-elicited craving and cue reactivity as predictors of naturally occurring smoking behavior. Addict Behav. 2009;34:536–41.
pubmed: 19395178 pmcid: 2685198 doi: 10.1016/j.addbeh.2009.03.022
Nader K, Schafe GE, Le Doux JE. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature 2000;406:722–6.
pubmed: 10963596 doi: 10.1038/35021052
Vallejo AG, Kroes MC, Rey E, Acedo MV, Moratti S, Fernández G, et al. Propofol-induced deep sedation reduces emotional episodic memory reconsolidation in humans. Sci Adv. 2019;5:eaav3801.
doi: 10.1126/sciadv.aav3801
Auchter AM, Shumake J, Gonzalez-Lima F, Monfils MH. Preventing the return of fear using reconsolidation updating and methylene blue is differentially dependent on extinction learning. Sci Rep. 2017;7:46071.
pubmed: 28397861 pmcid: 5387397 doi: 10.1038/srep46071
Elsey J, Filmer AI, Galvin HR, Kurath JD, Vossoughi L, Thomander LS, et al. Reconsolidation-based treatment for fear of public speaking: a systematic pilot study using propranolol. Transl Psychiatry. 2020;10:1–12.
doi: 10.1038/s41398-020-0857-z
Fan HY, Cherng CG, Yang FY, Cheng LY, Tsai CJ, Lin LC, et al. Systemic treatment with protein synthesis inhibitors attenuates the expression of cocaine memory. Behav Brain Res. 2010;208:522–7.
pubmed: 20060424 doi: 10.1016/j.bbr.2009.12.034
Valjent E, Corbille AG, Bertran-Gonzalez J, Herve D, Girault JA. Inhibition of ERK pathway or protein synthesis during reexposure to drugs of abuse erases previously learned place preference. Proc Natl Acad Sci USA. 2006;103:2932–7.
pubmed: 16473939 pmcid: 1413817 doi: 10.1073/pnas.0511030103
Sorg BA. Reconsolidation of drug memories. Neurosci Biobehav Rev. 2012;36:1400–17.
pubmed: 22342780 pmcid: 3526670 doi: 10.1016/j.neubiorev.2012.02.004
Thonberg H, Fredriksson JM, Nedergaard J, Cannon B. A novel pathway for adrenergic stimulation of cAMP-response-element-binding protein (CREB) phosphorylation: mediation via alpha1-adrenoceptors and protein kinase C activation. Biochem J. 2002;364:73–9.
pubmed: 11988078 pmcid: 1222547 doi: 10.1042/bj3640073
Elsey JWB, Kindt M. Tackling maladaptive memories through reconsolidation: from neural to clinical science. Neurobiol Learn Mem. 2017;142:108–17.
pubmed: 28302564 doi: 10.1016/j.nlm.2017.03.007
Lonergan MH, Olivera-Figueroa LA, Pitman RK, Brunet A. Propranolol’s effects on the consolidation and reconsolidation of long-term emotional memory in healthy participants: a meta-analysis. J Psychiatry Neurosci. 2013;38:222–31.
pubmed: 23182304 pmcid: 3692719 doi: 10.1503/jpn.120111
Dębiec J, Ledoux JE. Disruption of reconsolidation but not consolidation of auditory fear conditioning by noradrenergic blockade in the amygdala. Neuroscience. 2004;129:267–72.
pubmed: 15501585 doi: 10.1016/j.neuroscience.2004.08.018
Brunet A, Saumier D, Liu A, Streiner DL, Tremblay J, Pitman RK. Reduction of PTSD symptoms with pre-reactivation propranolol therapy: a randomized controlled trial. Am J Psychiatry. 2018;175:427–33.
pubmed: 29325446 doi: 10.1176/appi.ajp.2017.17050481
Mahabir M, Tucholka A, Shin LM, Etienne P, Brunet A. Emotional face processing in post-traumatic stress disorder after reconsolidation impairment using propranolol: a pilot fMRI study. J Anxiety Disord. 2015;36:127–33.
pubmed: 26551661 doi: 10.1016/j.janxdis.2015.10.004
Levy DA, Mika R, Radzyminski C, Ben-Zvi S, Tibon R. Behavioral reconsolidation interference with episodic memory within-subjects is elusive. Neurobiol Learn Mem. 2018;150:75–83.
pubmed: 29522808 pmcid: 5906735 doi: 10.1016/j.nlm.2018.03.004
Schroyens N, Beckers T, Kindt M. In search for boundary conditions of reconsolidation: a failure of fear memory interference. Front Behav Neurosci. 2017;11:65.
pubmed: 28469565 pmcid: 5395559 doi: 10.3389/fnbeh.2017.00065
Lonergan M, Saumier D, Tremblay J, Kieffer B, Brown TG, Brunet A. Reactivating addiction-related memories under propranolol to reduce craving: a pilot randomized controlled trial. J Behav Ther Exp Psychiatry. 2016;50:245–9.
pubmed: 26454715 doi: 10.1016/j.jbtep.2015.09.012
Robinson MJF, Franklin KBJ. Central but not peripheral beta-adrenergic antagonism blocks reconsolidation for a morphine place preference. Behav Brain Res. 2007;182:129–34.
pubmed: 17604134 doi: 10.1016/j.bbr.2007.05.023
Taylor JR, Olausson P, Quinn JJ, Torregrossa MM. Targeting extinction and reconsolidation mechanisms to combat the impact of drug cues on addiction. Neuropharmacology. 2009;56:186–95.
pubmed: 18708077 doi: 10.1016/j.neuropharm.2008.07.027
Saladin ME, Gray KM, McRae-Clark AL, Larowe SD, Yeatts SD, Baker NL, et al. A double blind, placebo-controlled study of the effects of post-retrieval propranolol on reconsolidation of memory for craving and cue reactivity in cocaine dependent humans. Psychopharmacology. 2013;226:721–37.
pubmed: 23460266 pmcid: 3637960 doi: 10.1007/s00213-013-3039-3
Zhao LY, Sun LL, Shi J, Li P, Zhang Y, Lu L. Effects of β-adrenergic receptor blockade on drug-related memory reconsolidation in abstinent heroin addicts. Drug Alcohol Depend. 2011;118:224–9.
pubmed: 21531091 doi: 10.1016/j.drugalcdep.2011.03.025
Xue YX, Deng JH, Chen YY, Zhang LB, Wu P, Huang GD, et al. Effect of selective inhibition of reactivated nicotine-associated memories with propranolol on nicotine craving. JAMA Psychiatry. 2017;74:224–32.
pubmed: 28146250 pmcid: 6201291 doi: 10.1001/jamapsychiatry.2016.3907
Schwabe L, Nader K, Wolf OT, Beaudry T, Pruessner JC. Neural signature of reconsolidation impairments by propranolol in humans. Biol Psychiatry. 2012;71:380–6.
pubmed: 22129757 doi: 10.1016/j.biopsych.2011.10.028
Schiller D, Kanen JW, LeDoux JE, Monfils MH, Phelps EA. Extinction during reconsolidation of threat memory diminishes prefrontal cortex involvement. Proc Natl Acad Sci USA. 2013;110:20040–5.
pubmed: 24277809 pmcid: 3864277 doi: 10.1073/pnas.1320322110
Agren T, Engman J, Frick A, Björkstrand J, Larsson EM, Furmark T, et al. Disruption of reconsolidation erases a fear memory trace in the human amygdala. Science 2012;337:1550–2.
pubmed: 22997340 doi: 10.1126/science.1223006
Björkstrand J, Agren T, Frick A, Engman J, Larsson EM, Furmark T, et al. Disruption of memory reconsolidation erases a fear memory trace in the human amygdala: an 18-month follow-up. PLoS ONE. 2015;10:0129393.
doi: 10.1371/journal.pone.0129393
Björkstrand J, Agren T, Åhs F, Frick A, Larsson EM, Hjorth O, et al. Disrupting reconsolidation attenuates long-term fear memory in the human amygdala and facilitates approach behavior. Curr Biol: CB. 2016;26:2690–5.
pubmed: 27568591 doi: 10.1016/j.cub.2016.08.022
Kroes MC, Tona KD, den Ouden HE, Vogel S, van Wingen GA, Fernández G. How administration of the beta-blocker propranolol before extinction can prevent the return of fear. Neuropsychopharmacology. 2016;41:1569–78.
pubmed: 26462618 doi: 10.1038/npp.2015.315
Mohseni M. Use of vitamin C as placebo in anesthesiology. Anesth Pain Med. 2013;2:141.
pubmed: 24244926 pmcid: 3821127
Deng J, Shi L, Yuan K, Yao P, Chen S, Que J, et al. Propranolol-induced inhibition of unconditioned stimulus-reactivated fear memory prevents the return of fear in humans. Transl Psychiatry. 2020;10:345.
pubmed: 33051441 pmcid: 7555531 doi: 10.1038/s41398-020-01023-w
Kindt M, Soeter M, Vervliet B. Beyond extinction: erasing human fear responses and preventing the return of fear. Nat Neurosci. 2009;12:256–8.
pubmed: 19219038 doi: 10.1038/nn.2271
Paterson JW, Conolly ME, Dollery CT, Hayes A, Cooper RG. The pharmacodynamics and metabolism of propranolol in man. Pharmacologia Clin. 1970;2:127–33.
doi: 10.1007/BF00420338
Rao L-L, Zhou Y, Xu L, Liang ZY, Jiang T, Li S. Are risky choices actually guided by a compensatory process? new insights from fMRI. PLoS ONE. 2011;6:14756.
doi: 10.1371/journal.pone.0014756
Wang Y, Zhong S, Jia Y, Sun Y, Wang B, Liu T, et al. Disrupted resting-state functional connectivity in nonmedicated bipolar disorder. Radiology. 2016;280:529–36.
pubmed: 26909649 doi: 10.1148/radiol.2016151641
Rao L-L, Dunn JC, Zhou Y, Li S. The neural correlates of risky decision making across short and long runs. Sci Rep. 2015;5:15831.
pubmed: 26516095 pmcid: 4626783 doi: 10.1038/srep15831
Kuhn S, Gallinat J. Common biology of craving across legal and illegal drugs - a quantitative meta-analysis of cue-reactivity brain response. Eur J Neurosci. 2011;33:1318–26.
pubmed: 21261758 doi: 10.1111/j.1460-9568.2010.07590.x
Jasinska AJ, Stein EA, Kaiser J, Naumer MJ, Yalachkov Y. Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies. Neurosci Biobehav Rev. 2014;38:1–16.
pubmed: 24211373 doi: 10.1016/j.neubiorev.2013.10.013
Franklin TR, Wang Z, Li Y, Suh JJ, Goldman M, Lohoff FW, et al. Dopamine transporter genotype modulation of neural responses to smoking cues: confirmation in a new cohort. Addict Biol. 2011;16:308–22.
pubmed: 21299752 pmcid: 3348624 doi: 10.1111/j.1369-1600.2010.00277.x
Hartwell KJ, Johnson KA, Li X, Myrick H, LeMatty T, George MS, et al. Neural correlates of craving and resisting craving for tobacco in nicotine dependent smokers. Addict Biol. 2011;16:654–66.
pubmed: 21790899 pmcid: 3182826 doi: 10.1111/j.1369-1600.2011.00340.x
Ferry B, Roozendaal B, McGaugh JL. Basolateral amygdala noradrenergic influences on memory storage are mediated by an interaction between beta- and alpha1-adrenoceptors. J Neurosci. 1999;19:5119–23.
pubmed: 10366644 pmcid: 6782651 doi: 10.1523/JNEUROSCI.19-12-05119.1999
O’Donnell T, Hegadoren KM, Coupland NC. Noradrenergic mechanisms in the pathophysiology of post-traumatic stress disorder. Neuropsychobiology. 2004;50:273–83.
pubmed: 15539856 doi: 10.1159/000080952
Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A, Marmar CR. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry. 2003;54:947–9.
pubmed: 14573324 doi: 10.1016/S0006-3223(03)00412-8
Auber A, Tedesco V, Jones CE, Monfils M-H, Chiamulera C. Post-retrieval extinction as reconsolidation interference: methodological issues or boundary conditions? Psychopharmacology. 2013;226:631–47.
pubmed: 23404065 pmcid: 3682675 doi: 10.1007/s00213-013-3004-1
Walker MP, Stickgold R. Understanding the boundary conditions of memory reconsolidation. Proc Natl Acad Sci USA. 2016;113:E3991–2.
pubmed: 27364011 pmcid: 4948330 doi: 10.1073/pnas.1607964113
Zuccolo PF, Hunziker MHL. A review of boundary conditions and variables involved in the prevention of return of fear after post-retrieval extinction. Behav Process. 2019;162:39–54.
doi: 10.1016/j.beproc.2019.01.011
Chiamulera C, Tedesco V, Zangrandi L, Giuliano C, Fumagalli G. Propranolol transiently inhibits reinstatement of nicotine-seeking behaviour in rats. J Psychopharmacol. 2010;24:389–95.
pubmed: 18832430 doi: 10.1177/0269881108097718
Kampman KM, Volpicelli JR, Mulvaney F, Alterman AI, Cornish J, Gariti P, et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend. 2001;63:69–78.
pubmed: 11297832 doi: 10.1016/S0376-8716(00)00193-9
Jobes ML, Aharonovich E, Epstein DH, Phillips KA, Reamer D, Anderson M, Preston KL. Effects of prereactivation propranolol on cocaine craving elicited by imagery script/cue sets in opioid-dependent polydrug users: a randomized study. J Addict Med. 2015;9:491–8.
pubmed: 26501788 pmcid: 4630075 doi: 10.1097/ADM.0000000000000169
Rodriguez-Romaguera J, Sotres-Bayon F, Mueller D, Quirk GJ. Systemic propranolol acts centrally to reduce conditioned fear in rats without impairing extinction. Biol Psychol. 2009;65:887–92.
doi: 10.1016/j.biopsych.2009.01.009
Bos MG, Beckers T, Kindt M. The effects of noradrenergic blockade on extinction in humans. Biol Psychol. 2012;89:598–605.
pubmed: 22321909 doi: 10.1016/j.biopsycho.2012.01.007
Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2008;42:503–6.
pubmed: 17588604 doi: 10.1016/j.jpsychires.2007.05.006
Thomas É, Saumier D, Pitman RK, Tremblay J, Brunet A. Consolidation and reconsolidation are impaired by oral propranolol administered before but not after memory (re)activation in humans. Neurobiol Learn Mem. 2017;142:118–25.
pubmed: 28003127 doi: 10.1016/j.nlm.2016.12.010
Kindt M, Soeter M. Pharmacologically induced amnesia for learned fear is time and sleep dependent. Nat Commun. 2018;9:1–10.
doi: 10.1038/s41467-018-03659-1
Soeter M, Kindt M. Stimulation of the noradrenergic system during memory formation impairs extinction learning but not the disruption of reconsolidation. Neuropsychopharmacology. 2012;37:1204–15.
pubmed: 22169947 doi: 10.1038/npp.2011.307
Thomas E, Saumier D, Pitman RK, Tremblay J, Brunet A. Consolidation and reconsolidation are impaired by oral propranolol administered before but not after memory (re)activation in humans. Neurobiol Learn Mem. 2017;142:118–25.
pubmed: 28003127 doi: 10.1016/j.nlm.2016.12.010
Pachas GN, Gilman J, Orr SP, Hoeppner B, Carlini SV, Grasser EB, et al. Single dose propranolol does not affect physiologic or emotional reactivity to smoking cues. Psychopharmacology. 2015;232:1619–28.
pubmed: 25413896 doi: 10.1007/s00213-014-3797-6

Auteurs

Xiao Lin (X)

Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, 100191, Beijing, China.

Jiahui Deng (J)

Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, 100191, Beijing, China.

Kai Yuan (K)

Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, 100191, Beijing, China.

Qiandong Wang (Q)

Beijing Key Laboratory of Applied Experimental Psychology, National Demonstration Center for Experimental Psychology Education (Beijing Normal University), Faculty of Psychology, Beijing Normal University, 100875, Beijing, China.

Lin Liu (L)

Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, 100191, Beijing, China.

Yanping Bao (Y)

National Institute on Drug Dependence and Beijing Key Laboratory on Drug Dependence Research, Peking University, 100191, Beijing, China.

Yanxue Xue (Y)

National Institute on Drug Dependence and Beijing Key Laboratory on Drug Dependence Research, Peking University, 100191, Beijing, China.

Peng Li (P)

Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, 100191, Beijing, China.

Jianyu Que (J)

Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, 100191, Beijing, China.

Jiajia Liu (J)

Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, 100191, Beijing, China.

Wei Yan (W)

Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, 100191, Beijing, China.

Hongqiang Sun (H)

Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, 100191, Beijing, China.

Ping Wu (P)

National Institute on Drug Dependence and Beijing Key Laboratory on Drug Dependence Research, Peking University, 100191, Beijing, China.

Jie Shi (J)

National Institute on Drug Dependence and Beijing Key Laboratory on Drug Dependence Research, Peking University, 100191, Beijing, China.

Le Shi (L)

Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, 100191, Beijing, China. leshi@bjmu.edu.cn.

Lin Lu (L)

Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, 100191, Beijing, China. linlu@bjmu.edu.cn.
National Institute on Drug Dependence and Beijing Key Laboratory on Drug Dependence Research, Peking University, 100191, Beijing, China. linlu@bjmu.edu.cn.
Peking-Tsinghua Center for Life Sciences and PKU-IDG/McGovern Institute for Brain Research, 100191, Beijing, China. linlu@bjmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH